Case Study 1 — The Marketing Layer That Grew on a Regulatory Opening
A structural case. No individual, company, clinic, service, or platform is named, and none needs to be. Everything below is a description of an arrangement. If you find yourself supplying names as you read, notice the impulse and set it down: the value of this case is that it will still be legible the next time it happens with a different molecule and different participants, and a case built around names would not be.
Scope note. Chapter 12 owns the pharmacology, the legal basis, and the safety record. This case study assumes all of it and examines only what was built on top: the marketing.
1. The conditions
Four things were true at the same time, and none of them individually was unusual.
A drug class became culturally central. Demand for a category of metabolic medicine rose far beyond any forecast, driven partly by clinical results that were genuinely impressive and partly by a cultural moment that Chapter 41 examines on its own terms.
Supply could not meet it. Manufacturing capacity for these molecules is not elastic on a twelve-month horizon. The approved products entered formal shortage status.
Shortage status opened a narrow legal door. In the relevant jurisdiction, the rules governing pharmacy compounding contain a conditional allowance tied to shortage: preparations of a molecule that would ordinarily be off-limits, because a commercially available approved version exists, become permissible while that version is listed as unavailable. The allowance is narrow, conditional, and explicitly temporary — it exists so patients are not stranded, and it is written to close when the shortage does.
And the molecules are comparatively easy to make. As Chapter 1 §1.7 established, the barrier to synthesizing a peptide is much lower than the barrier to producing a biologic. Capacity appeared quickly, and it appeared in more places than a regulator can inspect on a short timescale.
Note what has and has not happened at this point. A legal opening exists. Supply exists. Demand exists for the approved product, but not yet for the compounded one, because most people did not know it existed. That gap — between supply that is available and demand that has not yet been directed at it — is precisely the gap that marketing fills. Everything that follows is what filling it looked like.
2. What was built
The structure that appeared was the funnel of §42.1, assembled quickly and competently from components that already existed for other product categories.
At the attention step: short-form video and social content in enormous volume. Some produced by the selling entities directly. Much more produced by creators under affiliate and sponsorship arrangements, in fitness, beauty, lifestyle, parenting, and comedy niches — audiences built entirely on unrelated content, whose trust had accumulated over years with no commercial stake attached (§42.3).
At the interest step: two claim-forms did most of the work.
The first was price. The compounded preparation was framed against the list price of the approved product, and this framing was powerful because it was substantially true for many people. Coverage for these medicines was inconsistent and frequently excluded the indication a given patient had (Chapter 12). For a person facing a cost they could not meet, a cheaper route is not a temptation. It is the only route.
The second was equivalence, delivered through the vocabulary §42.8 catalogs: "the same active ingredient," "compounded," sometimes "generic," and — as the door began to close — "personalized" and "customized." Each of these words has a legitimate use. Each was doing work in this context that its legitimate use does not license.
At the consultation step: an asynchronous intake form, often free or nominally priced, reviewed by a licensed clinician. This step is the one that transformed the transaction from a purchase into a prescription, and it is the one designed to take the least time.
At the prescription and subscription steps: monthly recurring billing, automatic refills, and retention content aimed at the people already paying — the invisible category from §42.9's third question.
3. The inversion at the center
Here is the feature of this episode most worth carrying forward, and it is the one that surprises almost everyone the first time.
Much of what was said in that advertising would have been unlawful coming from the manufacturer of the approved product.
Not because anyone decided the compounded version should be held to a lower standard. Because promotional rules attach to an approval. A manufacturer's claims are tethered to an approved label, must present risk information with fair balance, may not extend to unapproved uses, and are subject to a submission and enforcement apparatus built for exactly that purpose (§42.7, Chapter 38). A preparation with no approval has no label to be tethered to. It falls back to general advertising law, which prohibits deception but is far less specific about what may be claimed for a medicine and by whom.
The absence of an approval loosened the constraints on speech rather than tightening them. Read that twice. It is the opposite of what the intuitive model predicts, it is a real property of how these regimes fit together, and it will be true again in the next episode of the same kind.
4. Who was paid, at which step
Map the structure with the §42.1 columns and the picture is unremarkable — which is the point. Every role below is an ordinary commercial role.
- The creator was paid per click, per completed intake, per first fill, or as a share of recurring revenue. Which of those it was determined whether their content emphasized curiosity, signup, purchase, or persistence.
- The prescribing clinician was typically compensated per encounter reviewed, inside a business whose revenue depended on fills.
- The preparing pharmacy was paid per unit prepared.
- The dispensing and billing entity collected monthly, and held the lifetime value.
- The platform was paid for the attention, twice: once for the organic distribution it monetized and once for the paid promotion layered on top.
Nobody in that list has to have done anything wrong for the aggregate outcome to be bad. They did not need to coordinate; several of them never communicated. What connected them was a shared interest in the same outcome, which is more durable than agreement.
5. What the structure could not do
Three failures were architectural rather than behavioral.
It could not detect a product-quality problem. Identity, purity, concentration accuracy, sterility, and stability are the documented failure modes in unapproved peptide supply (Chapters 19 and 34). None of them is visible to a creator, an intake form, or a subscriber, and none of them produces a signal that travels back up the funnel.
It could not receive an adverse event. A referral relationship has a comment section, not a pharmacovigilance system (§42.6). The people for whom it went badly mostly left quietly, which means the visible testimony was a sample filtered by willingness to keep talking.
And it could not say no. An intake designed for conversion has a very low rate of producing a negative result, and no participant in the structure had a commercial reason to want a higher one.
6. When the door closed
Supply recovered. Shortage status ended. The legal permission narrowed, and the specific product line that had justified the structure became largely impermissible.
The marketing layer did not dissolve, because a marketing layer is an asset. It consists of channels, audiences, creative inventory, affiliate relationships, intake software, and staff, none of which lose their value when one product line ends. It migrated: toward combination and "personalized" framings that sit differently in the rules; toward adjacent molecules with thinner evidence and no shortage history; toward jurisdictions with looser constraints; and toward categories where efficacy language is least regulated.
That is not a scandal. It is what a marketing layer is for, and predicting it requires no cynicism about anyone's character — only an understanding of what kind of asset had been built.
7. The part that is genuinely contested
An honest case study has to include the parts where the chapter's frame is weakest.
Many patients were served. People who could not obtain or afford the approved product obtained treatment, and for an unknown but non-trivial number of them it worked as intended. The counterfactual for those patients was not "the approved product." It was nothing.
Compounding is a legitimate and long-standing practice. It exists because real patients need preparations that manufactured products do not supply — a different concentration, an excipient they react to, a form they can swallow. An account that treats the whole category as illegitimate is wrong about medicine.
And the demand was real. It was not conjured by advertising. Advertising directed pre-existing demand toward an available supply, which is the ordinary function of advertising. A person choosing an imperfectly assured version of a medicine they cannot otherwise obtain is behaving rationally under constraints somebody else set — a pricing failure and a coverage failure, not a failure of intelligence. Any analysis that calls those patients gullible has misidentified the problem and will mispredict what happens next.
Discussion questions
1. The case argues that the four opening conditions were each individually unremarkable. Which single condition, if removed, would most reliably have prevented the marketing layer from forming — and what does your answer imply about where an intervention would have to sit?
2. Explain the §3 inversion to someone who finds it absurd that a product with less regulatory scrutiny faces fewer restrictions on what may be claimed for it. Then argue the other side: what would go wrong if promotional rules were extended to entities with no approval to be tethered to?
3. In §4, every participant is doing an ordinary commercial job and none of them needs to coordinate with the others. Identify the point in the structure where a single change in compensation would most alter the aggregate behavior, and say what it would cost the entity that made the change.
4. §5 lists three architectural failures. For each, design the minimum mechanism that would have detected the problem, and state who would have to pay for it and why they would not want to.
5. The case predicts migration rather than dissolution when a regulatory opening closes. State a public-information test of that prediction, specify in advance what result would falsify it, and identify the most likely way your test would mislead you.
6. §7 argues that patients using compounded preparations were often behaving rationally under constraints set by others. Take that seriously and follow it: if the demand was real and the pricing and coverage failures were real, what does an effective response to this episode look like — and what does it imply about interventions aimed at the marketing layer alone?